BC Platforms Partners with OmicsBank to Expand Access to Multi-Omics Data from India and UAE
核心洞察
BC Platforms (搜索) announced a strategic partnership with OmicsBank (搜索) to access large-scale real-world clinical and multi-omics datasets from India and the UAE, expanding their global patient catchment to over 187 million patient lives.
The collaboration addresses significant underrepresentation of South Asian populations in global genome-wide association studies, where they account for less than 2% of participants despite representing nearly 20% of the world's population.
The partnership provides access to millions of patient electronic medical records, pathology slides, medical images, and sequencing data that can support AI model development and precision medicine research across diverse populations.
BC Platforms (搜索), a global leader in healthcare data and analytics, has announced a strategic partnership with OmicsBank (搜索) to expand access to large-scale real-world clinical and multi-omics datasets from India and the United Arab Emirates. The collaboration significantly enhances BC Platforms' global patient catchment, adding more than 12 million patient lives from India and approximately 500,000 from the UAE to their existing network of over 187 million patients across 35 countries.
Addressing Critical Data Gaps in Global Research
The partnership directly tackles a significant disparity in global medical research representation. Despite India accounting for nearly 20% of the world's population and playing an increasingly important role in global drug development, South Asian populations represent less than approximately 2% of participants in global genome-wide association studies.
"India's population scale, disease diversity, and growing role in clinical research makes it invaluable from a scientific and regulatory perspective – and critical for life science companies that are seeking innovative targeted therapies and pursuing precision medicine strategies," said Mukhtar Ahmed, CEO of BC Platforms (搜索).
Comprehensive Multi-Modal Dataset Access
The OmicsBank (搜索) datasets encompass millions of patient electronic medical records (EMRs), large-scale collections of pathology slides and medical images, extensive sequencing data, and connected biospecimens. These datasets can be provisioned either as modular datasets for specific research use cases or as comprehensive longitudinal cohorts to support advanced analytics and the development of multimodal AI models in healthcare.
When integrated into BC Platforms (搜索)' agentic-AI data mastering platform, BC Unify, these datasets can be harmonized and provisioned via BC Mosaic (federated trusted research environments) and BC Catalyst (insights and predictive analytics). This integration supports users across the entire drug development spectrum, from early discovery and feasibility studies to clinical development, real-world performance insights, post-market evidence generation, and large-scale AI model training.
Strategic Importance for Precision Medicine
India's genetic and disease diversity, coupled with a high burden of non-communicable diseases – notably cardiovascular disease (搜索), diabetes (搜索), and cancer (搜索) – make it a critical market for medical research and development. The continued reliance on US and European ancestry datasets limits the generalizability of findings and constrains the applicability of precision-medicine approaches in globally diverse populations.
"At OmicsBank (搜索), our focus has always been on building AI-ready data infrastructure that unlocks the full value of real-world and multi-omics data from emerging markets in a responsible and scalable way," said Sumit Sinha, CEO of OmicsBank. "Partnering with BC Platforms (搜索) allows us to extend this capability globally and help ensure that diverse patient populations are more accurately represented across the drug development lifecycle."
Expanding Global Reach
The partnership includes plans for further expansion across India and additional datasets from Saudi Arabia, Taiwan, the Philippines, and Malaysia as OmicsBank (搜索) continues to grow its hospital and diagnostic laboratory partnerships. Therapeutic area coverage spans oncology, cardiometabolic and cardiovascular diseases, neurology, immunology, and rare diseases, helping to accelerate research and evidence generation across the full drug lifecycle.
As regulators and payers increasingly expect robust real-world evidence to support feasibility, safety, and effectiveness assessments, access to high-quality patient data from India becomes essential to minimize the potential for bias in Western-centric evidence and support truly global development strategies. The collaboration enables secure access to large-scale, research-ready datasets from India, driving more representative cohort selection, improved feasibility assessments, and more cost-efficient research across the drug lifecycle.